Definium Therapeutics, Inc. 8-K

What Happened

• On May 7, 2026, Definium Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2026 via a press release and disclosed plans for a conference call to discuss those results and recent corporate highlights. The press release is furnished as Exhibit 99.1 to the Form 8-K. The filing was signed by CEO Robert Barrow.

Key Details

• Filing date: May 7, 2026.
• Reporting period: quarter ended March 31, 2026.
• Press release announcing results and conference call details furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed and filed by Robert Barrow, Chief Executive Officer.

Why It Matters

• The company has made its latest quarterly results public; investors should review the press release and consider joining the conference call for details on revenue, operating results, cash position, and any program or corporate updates disclosed.
• This 8-K is a routine disclosure that makes the quarterly results and related investor communication available through the SEC filing record.